Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7H3-IL7Ra CAR-T in Pediatric DIPG
NCT06221553Phase 1Recruiting
- Sponsor
- Chulalongkorn University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B7H3-IL7Ra CAR-T in diffuse intrinsic pontine glioma (DIPG), sponsored by Chulalongkorn University. Primary endpoint: Safety of B7H3-IL7Ra CAR T cells infusion at 28 days. Started Mar 2024; status: recruiting.
02
Drugs
B7H3-IL7Ra CAR-T
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT06221553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221553.